Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 6
Submit an article Journal homepage
53
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluation

Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions

Harvey D White Cardiology Department, Green Lane Hospital, Private Bag 92189, Auckland 1030, New Zealand
&
Derek P Chew Harvard School of Public Health, Boston, Massachusetts, USA
Pages 777-788 | Published online: 25 Feb 2005

Bibliography

  • THE HIRULOG AND EARLY REPERFUSION OR OCCLUSION (HERO)-2 TRIAL INVESTIGATORS: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet (2001) 358(9296):1855–1863.
  • ••Report of a large trial showing no effect ofbivalirudin on mortality but a significant reduction in reinfarction.
  • CANNON CP, WEINTRAUB WS, DEMOPOULOS LA et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl. I Med. (2001) 344(25):1879–1887.
  • KONG DF, TOPOL EJ, BITTL JA et al.: Clinical outcomes of bivalirudin for ischemic heart disease. Circulation (1999) 100(20):2049–2053.
  • ••Overview demonstrating increased efficacyand decreased bleeding with bivalirudin compared with heparin.
  • YOUNG E, WELLS P, HOLLOWAY S, WEITZ J, HIRSH J: Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb. Haemost. (1994) 71(3):300–304.
  • BATES SM, WEITZ JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Jim. j Cardiol (1998) 82(8B):12P–18P
  • •Review comparing hirudin and bivalirudin with heparin.
  • COHEN M, DEMERS C, GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. I Med. (1997) 337(7):447–452.
  • ANTMAN EM, MCCABE CH, GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation (1999) 100(15):1593–1601.
  • DELLBORG M, BERGSTRAND L, GRANGER C et al.: LMW heparin (dalteparin) for improvement of patency after thrombolysis in AMI: a prospective randomized multi-centre coronary angiography study. I Am. Coll Cardiol. (2001) 37(2, Suppl. A):369A. Abstract.
  • THE ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW THROMBOLYTIC REGIMEN (ASSENT)-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfraction-ated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358(9282):605–613.
  • SIMOONS ML, KRZEMINSKA-PAKULA M, ALONSO A et al: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction: the AMI-SK study. Eur. Heart J. (2002). In press.
  • ORGANISATION TO ASSESS STRATEGIES FOR ISCHEMIC SYNDROMES (OASIS-2) INVESTIGATORS: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet (1999) 353(9151):429–438.
  • MARAGANORE JM, BOURDON P, JABLONSKI I, RAMACHANDRAN KL, FENTON JW II: Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry (1990) 29(30):7095–7101.
  • WEITZ J, MARAGANORE J: The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation. Am. Cardiol. (2001) 88(Suppl. 5A):212. Abstract.
  • FOX I, DAWSON A, LOYNDS P et al: Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb. Haemost. (1993) 69(2):157–163.
  • MARAGANORE JM, ADELMAN BA: Hirulog : a direct thrombin inhibitor for management of acute coronary syndromes. Coron. Artery Dis. (1996) 7(6):438–448.
  • ROBSON R: The use of bivalirudin in patients with renal impairment. I Invasive Cardiol. (2000) 12(Suppl. F):33F–36F.
  • •Analysis of bleeding and renal function with bivalirudin.
  • GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO (GISSI): GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet (1990) 336(8707):65–71.
  • FUCHS J, CANNON CP, AND THE TIMI 7 INVESTIGATORS: Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischaemia (TIMI) 7 Trial. Circulation (1995) 92(4):727–733.
  • TOPOL EJ, BONAN R, JEWITT D et al: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation (1993) 87(5):1622–1629.
  • •First study of bivalirudin in patients undergoing PCI.
  • LIDON RIVI, THEROUX P, LESPERANCE J et al.: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation (1994) 89(4):1567–1572.
  • WHITE HD, AYLWARD PE, FREY MJ et al.: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation (1997) 96(7):2155–2161.
  • •Angiographic study to determine the design of the HERO-2 study.
  • THEROUX P, PEREZ-VILLA F, WATERS D et al.: Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation (1995) 91(8):2132–2139.
  • MARAGANORE JM et at. Heparin variability and resistance: comparison with a direct thrombin inhibitor. Circulation (1992) 86(Suppl. I):I-386. Abstract
  • MARAGANORE JM: preclinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor. Adv. Exp. Med. Biol. (1993) 340:227–236.
  • SHARMA GVRK, LAPSLEY D, VITA JA et al.: Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am. J. Cardiol. (1993) 72(18):1357–1360.
  • LIDON RIVI, THEROUX P, JUNEAU M, ADELMAN B, MARAGANORE J: Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation (1993) 88(4, Part 1):1495–1501.
  • ANTMAN EM, MCCABE CH, BRAUNWALD E, for the TIMI-8 Investigators: Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI-8 trial. Am. Heart J. (2002) 143(2):229–234.
  • WHITE HD: Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin. Am. Heart J(2002) 143(2):189–192. Editorial.
  • CANNON CP, MARAGANORE JM, LOSCALZO J et al: Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am. J. Cardiol. (1993) 71(10):778–782.
  • BITTL JA: Bivalirudin for percutaneous coronary interventions: development perspective. J. Invasive. Cardiol. (2000) 12(Suppl. F):2F–6F.
  • BITTL JA, STRONY J, BRINKER JA et al.: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N. Engl. J. Med. (1995) 333(12):764–769.
  • ••Study showing the efficacy of bivalirudinin patients with post-MI angina.
  • BITTL JA, CHAITMAN BR, FEIT F et al.: Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J. (2001) 142(6):952–959.
  • ••Post hoc analysis of the prematurelystopped Bivalirudin Angioplasty Study, demonstrating a reduction in major events, including bleeding, in patients with unstable angina. This reanalysis presents the data as analysed for government filings and regulatory approval in the US.
  • ANTMAN EM, BRAUNWALD E: A second look at bivalirudin. Am. Heart J. (2001) 142(6):929–931.Expert Op/n. Pharmacother. (2002) 3(6)
  • LAUER MA: Cost analysis of bivalirudin in percutaneous coronary intervention. j. Invasive. Cardiol (2000) 12(Suppl. F):37F–40F.
  • CHESEBRO JH, KNATTERUD G, ROBERTS R et al.: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation (1987) 76(1):142–154.
  • HUDSON MP, GRANGER CB, TOPOL EJ et al.: Early reinfarction after fibrinolysis: experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Trials. Circulation (2001) 104(11):1229–1235.
  • LEE KL, WOODLIEF LH, TOPOL EJ et al.: Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation (1995) 91(6):1659–1668.
  • KLEIMAN NS, LINCOFF AM, HARRINGTON RA et al.: Antithrombin, antiplatelet therapy or both during PCI: a preliminary randomized trial. I. Am. Coll. Cardiol (2001) 37(2, Suppl. A):77A. Abstract.
  • LINCOFF AM, BITTL JA, KLEIMAN NS et al.: The REPLACE 1 Trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. Am. Coll Cardiol (2002) 39(5, Suppl. A):16A-17A. Abstract.
  • RAO AK, PRATT C, BERKE A et al: Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Am. Coll. Cardiol (1988) 11(1):1–11.
  • CAMPBELL KR, MAHAFFEY KW, LEWIS BE et al.: Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J. Invasive Cardiol (2000) 12(Suppl. F):14F–19F.
  • KOTTKE-MARCHANT K, LINCOFF AM, KLEIMAN N, ET AL: Direct thrombin inhibition by bivalirudin compared with abciximab, a GPIIb/IIIa antagonist, during percutaneous coronary intervention: favorable hemostatic profile compared to heparin/abciximab. Blood (1999) 94\(Suppl. 1, Part 1):623.
  • ORMISTON JA, SHAW BL, PANTHER MJ et al.: Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal and early ambulation: a feasibility study with implications for day-stay. Catheter Cardiovasc. Interv. (2002) 55(3):289–293.

Websites

  • www.medsafe.govt.nz/profs/datasheet/a/ angiomaxinj.htm Information for health professionals: data sheet: Angiomax (bivalirudin). The Medicines Company (NZ) Limited (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.